UK WINNERS & LOSERS SUMMARY: Tui Rises As Tips "Normal" Summer Trading

Mon, 04th Jan 2021 10:44

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.

----------

FTSE 100 - WINNERS

----------

Entain, up 26%. The gambling firm confirmed it received takeover interest from US partner MGM. Entain said the offer represents a value of 1,383 pence per share, a 22% premium to its 1,133.50p closing price on New Year's Eve. Entain shares were up 27% at 1,434.00p each on Monday morning. MGM's bid "undervalues" the company, Entain said.

----------

Polymetal International and Fresnillo, up 9.1% and 6.9%, respectively. The miners rose on the back of a rally in gold prices on Monday. An ounce of gold fetched USD1,929.22 on Monday morning, up from USD1,894.00 at the London market close on Thursday.

----------

FTSE 250 - WINNERS

----------

Tui, up 9.7%. In an interview with German publication Rheinische Post, the tour operator's executive chair, Fritz Joussen, said he expects the crucial summer period to be "relatively normal" for the travel industry due to Covid-19 vaccine rollouts.

----------

Future, up 3.1%. The media firm's GBP594 million takeover of GoCo Group - which owns Gocompare.com, Look After My Bills and MyVoucherCodes - has gained approval from the UK Financial Conduct Authority.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

Griffin Mining, up 17%. The miner announced that its new mining licence, covering zone two and zone three of the Caijiaying mine has been approved by the Chinese Ministry of Land & Natural Resources. The new licence will allow the mining of significant additional resources.

----------

EQTEC, up 17%. The waste-to-energy firm said it has secured a GBP1.3 million unsecured term loan facility with shareholder Altair Group Investment. The 12 month facility has a 6% annual interest rate.

----------

Tiziana Life Sciences, up 9.3%. Completes clinical study of its Foralumab drug in Covid-19 patients. Topline data is expected in January, though anecdotal evidence says the drug was well-tolerated.

----------

By Eric Cunha; ericcunha@alliancenews.com